Aurobindo Pharma Ltd vs Gufic Biosciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Aurobindo Pharma Ltd is ₹ 1428 as of 05 May 15:30 . The P/E Ratio of Aurobindo Pharma Ltd changed from 20.1 on March 2024 to 15.7 on March 2023 . This represents a CAGR of -4.82% over 5 yearsThe P/E Ratio of Gufic BioSciences Ltd changed from 33 on March 2024 to 0 on March 2023 . This represents a CAGR of -100.00% over 5 years The Market Cap of Aurobindo Pharma Ltd changed from ₹ 63835 crore on March 2024 to ₹ 30351 crore on March 2023 . This represents a CAGR of -13.82% over 5 yearsThe Market Cap of Gufic BioSciences Ltd changed from ₹ 2839 crore on March 2024 to ₹ 0 crore on March 2023 . This represents a CAGR of -100.00% over 5 years The revenue of Aurobindo Pharma Ltd for the Dec '25 is ₹ 8833 crore as compare to the Sep '25 revenue of ₹ 8407 crore. This represent the growth of 5.07% The revenue of Gufic BioSciences Ltd for the Dec '25 is ₹ 232.2 crore as compare to the Sep '25 revenue of ₹ 239.17 crore. This represent the decline of -2.91% The ebitda of Aurobindo Pharma Ltd for the Dec '25 is ₹ 1896 crore as compare to the Sep '25 ebitda of ₹ 1800 crore. This represent the growth of 5.31% The ebitda of Gufic BioSciences Ltd for the Dec '25 is ₹ 33.77 crore as compare to the Sep '25 ebitda of ₹ 39.96 crore. This represent the decline of -15.49% The net profit of Aurobindo Pharma Ltd changed from ₹ 918.22 crore to ₹ 909.8 crore over 7 quarters. This represents a CAGR of -0.53% The net profit of Gufic BioSciences Ltd changed from ₹ 20.86 crore to ₹ 12.42 crore over 7 quarters. This represents a CAGR of -25.64% The Dividend Payout of Aurobindo Pharma Ltd changed from 7.53 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Gufic BioSciences Ltd changed from 2.19 % on March 2021 to 1.43 % on March 2025 . This represents a CAGR of -8.17% over 5 years .

About Aurobindo Pharma Ltd

Aurobindo Pharma Limited (APL), one of the world's top 5 manufacturers of semi synthetic penicillins was incorporated in December 1986 as a private limited company.
Mr. P.V.Ramaprasad Reddy, Mr. K.Nityananda Reddy and a small, highly committed group of professionals founded it.
APL is developing, manufacturing and marketing active pharmaceutical ingredients (APIs also referred as bulk actives), intermediates and generic formulations.
The company's robust product portfolio is spread over 6 major product areas encompassing (Antibiotics, Anti-Retro Virals, CVS, CNS, Gastroenterologicals, and Anti-Allergics) with around 65 APIs in the non-antibiotics and over 55 APIs in the antibiotic segment and the World Health Organization (WHO), Geneva, has also approved Aurobindo's products.
APL is running with 29 manufacturing plants across the world conforming to GMP/ISO regulations and an extremely well equipped 9 R&D facilities.

About Gufic BioSciences Ltd

Gufic Biosciences Limited is a prominent global pharmaceutical enterprise dedicated to delivering a broad spectrum of pharmaceutical services to its clients.
Renowned for its extensive range of pharmaceutical products, Gufic operates as a comprehensive solution provider in both domestic and international markets, supported by a robust distribution network.
The Company is ranked among the top 100 pharmaceutical companies in India. Gufic is a leading manufacturer of lyophilized injections in India, with a state-of-the-art automated lyophilization plant located in Navsari, Gujarat.
The Company was incorporated in July, 1984.
The recent addition of the Indore manufacturing facility has further solidified Gufic's position as one of the world's largest producers of lyophilized injections.

FAQs for the comparison of Aurobindo Pharma Ltd and Gufic BioSciences Ltd

Which company has a larger market capitalization, Aurobindo Pharma Ltd or Gufic BioSciences Ltd?

Market cap of Aurobindo Pharma Ltd is 82,950 Cr while Market cap of Gufic BioSciences Ltd is 2,879 Cr

What are the key factors driving the stock performance of Aurobindo Pharma Ltd and Gufic BioSciences Ltd?

The stock performance of Aurobindo Pharma Ltd and Gufic BioSciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aurobindo Pharma Ltd and Gufic BioSciences Ltd?

As of May 5, 2026, the Aurobindo Pharma Ltd stock price is INR ₹1428.2. On the other hand, Gufic BioSciences Ltd stock price is INR ₹287.1.

How do dividend payouts of Aurobindo Pharma Ltd and Gufic BioSciences Ltd compare?

To compare the dividend payouts of Aurobindo Pharma Ltd and Gufic BioSciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.